(MENAFN - PR Newswire)
OSLO, Nov. 16, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston
NeoAg Summit 2018Date: 16 November 2018 Presenter: Dr. Magnus Jäderberg, CMOPresentation time: 11:00 ETVenue: Hyatt Regency Cambridge, Boston.
Title: TG01, a neo-antigen specific vaccine targeting RAS mutations in solid tumours
Presentation slides will be available on www.targovax.com/Investors .
For further information, please contact:Renate Birkeli, Investor RelationsPhone: +47-922-61-624Email: Media and IR enquires:Andreas Tinglum - Corporate Communications (Norway)Phone: +47-9300-1773Email: Simon Conway/Stephanie Cuthbert - FTI Consulting (International)Phone: +44-20-3727-1000Email:
This information was brought to you by Cision http://news.cision.com
Also from this source Nov 01, 2018, 05:45 ET Targovax ASA: Third quarter 2018 Results... Oct 26, 2018, 04:14 ET Targovax ASA: Announcement of Third Quarter 2018 Financial Results... Explore More news releases in similar topics
- All Summer Health & Safety News Releases
- All Health
- General Business